microRNA Biomarkers as Potential Diagnostic Markers for Cancer - Genomic Biomarkers for Pharmaceutical Development - page 122

[184] Zhu S, Si ML, Wu H, Mo YY. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol
Chem 2007;282:14328-36.
[185] Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the
PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 2007;133:647-58.
[186] Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, et al. MicroRNA-21 (miR-21)
post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and
metastasis in colorectal cancer. Oncogene 2008;27:2128-36.
[187] Zheng Y, Cui L, Sun W, Zhou H, Yuan X, Huo M, et al. MicroRNA-21 is a new marker of circulating tumor
cells in gastric cancer patients. Cancer Biomark 2011;10:71-7.
[188] Zhou H, Guo JM, Lou YR, Zhang XJ, Zhong FD, Jiang Z, et al. Detection of circulating tumor cells in periph-
eral blood from patients with gastric cancer using microRNA as a marker. J Mol Med (Berl) 2010;88:709-17.
[189] Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, et al. Circulating microRNAs in
plasma of patients with gastric cancers. Br J Cancer 2010;102:1174-9.
[190] Surveillance, Epidemiology, and End Results (SEER) Program, < www.seer.cancer.gov >; 2012 [accessed
11.01.13].
[191] Anderson JC, Fortinsky RH, Kleppinger A, Merz-Beyus AB, Huntington III CG, Lagarde S. Predictors
of compliance with free endoscopic colorectal cancer screening in uninsured adults. J Gen Intern Med
2011;26:875-80.
[192] Ahlquist DA, Taylor WR, Mahoney DW, Zou H, Domanico M, Thibodeau SN, et al. The stool DNA test is
more accurate than the plasma septin 9 test in detecting colorectal neoplasia. Clin Gastroenterol Hepatol
2012;10: 272-7, e1.
[193] Berger BM, Ahlquist DA. Stool DNA screening for colorectal neoplasia: biological and technical basis for high
detection rates. Pathology 2012;44:80-8.
[194] Zou H, Taylor WR, Harrington JJ, Hussain FT, Cao X, Loprinzi CL, et al. High detection rates of colorectal
neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology 2009;136:459-70.
[195] Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, et al. Differential expression of microRNAs in plasma of
patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut 2009;58:1375-81.
[196] Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for
early detection of colorectal cancer. Int J Cancer 2010;127:118-26.
[197] Wang LG, Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver
metastasis. Cancer Epidemiol 2012;36:e61-7.
[198] Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of
human solid tumors deines cancer gene targets. Proc Natl Acad Sci USA 2006;103:2257-61.
[199] Pu XX, Huang GL, Guo HQ, Guo CC, Li H, Ye S, et al. Circulating miR-221 directly ampliied from plasma
is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J
Gastroenterol Hepatol 2010;25:1674-80.
[200] Kanaan Z, Rai SN, Eichenberger MR, Roberts H, Keskey B, Pan J, et al. Plasma miR-21: a potential diagnostic
marker of colorectal cancer. Ann Surg 2012;256:544-51.
[201] Nugent M, Miller N, Kerin MJ. Circulating miR-34a levels are reduced in colorectal cancer. J Surg Oncol
2012;106(8):947-52.
[202] Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, et al. Circulating plasma MiR-141 is a novel
biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One 2011;6:e17745.
[203] El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.
Gastroenterology 2007;132:2557-76.
[204] Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a
liver-speciic MicroRNA. Science 2005;309:1577-81.
[205] Gui J, Tian Y, Wen X, Zhang W, Zhang P, Gao J, et al. Serum microRNA characterization identiies miR-885-5p
as a potential marker for detecting liver pathologies. Clin Sci (Lond) 2011;120:183-93.
[206] Zhang Y, Jia Y, Zheng R, Guo Y, Wang Y, Guo H, et al. Plasma microRNA-122 as a biomarker for viral-, alco-
hol-, and chemical-related hepatic diseases. Clin Chem 2010;56:1830-8.
[207] Xu J, Wu C, Che X, Wang L, Yu D, Zhang T, et al. Circulating microRNAs, miR-21, miR-122, and miR-223, in
patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 2011;50:136-42.
[208] Qi P, Cheng SQ, Wang H, Li N, Chen YF, Gao CF. Serum microRNAs as biomarkers for hepatocellular carci-
noma in Chinese patients with chronic hepatitis B virus infection. PLoS One 2011;6:e28486.